C. May et al., Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin, NATURE, 406(6791), 2000, pp. 82-86
The stable introduction of a functional beta-globin gene in haematopoietic
stem cells could be a powerful approach to treat beta-thalassaemia(1) and s
ickle-cell disease(2). Genetic approaches aiming to increase normal beta-gl
obin expression in the progeny of autologous haematopoietic stem cells(3) m
ight circumvent the limitations and risks of allogeneic cell transplants(4)
. However, low-level expression, position effects and transcriptional silen
cing hampered the effectiveness of viral transduction of the human beta-glo
bin gene when it was linked to minimal regulatory sequences(5). Here we sho
w that the use of recombinant lentiviruses enables efficient transfer and f
aithful integration of the human beta-globin gene together with large segme
nts of its locus control region. In long-term recipients of unselected tran
sduced bone marrow cells, tetramers of two murine alpha-globin and two huma
n beta(A)-globin molecules account for up to 13% of total haemoglobin in ma
ture red cells of normal mice. In beta-thalassaemic heterozygous mice highe
r percentages are obtained (17% to 24%), which are sufficient to ameliorate
anaemia and red cell morphology. Such levels should be of therapeutic bene
fit in patients with severe defects in haemoglobin production.